Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Virus and human oncogenesis]

J Bourhis1, O Dupuis

  • 1Institut Gustave-Roussy (radiothérapie et pharmacologie moléculaire), Villejuif.

La Revue Du Praticien
|April 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durvalumab combined with weekly carboplatin/paclitaxel as first-line treatment of patients with recurrent and/or metastatic HNSCC not eligible for cisplatin-based chemotherapies: results of the multicenter prospective study FRAIL-IMMUNE.

ESMO open·2026
Same author

Discontinuation of the double-blind, placebo-controlled randomized, phase III GORTEC 2022-01 trial of radiotherapy-cetuximab and xevinapant in patients with locally advanced squamous cell carcinoma of the head and neck, unfit for cisplatin.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Clustering of dosimetric profiles reveals distinct local control probabilities after SABR in oligometastatic head and neck cancer: insights from the OMET phase II trial quality assurance Process.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

International guidelines for the delineation of the postoperative clinical target volumes (CTV) for parotid and submandibular gland cancers.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2025
Same author

[Proposal for the delineation of postoperative primary clinical target volumes in maxillary sinus and nasal cavity cancers].

Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique·2024
Same author

Impact of heterozygous ALK1 mutations on the transcriptomic response to BMP9 and BMP10 in endothelial cells from hereditary hemorrhagic telangiectasia and pulmonary arterial hypertension donors.

Angiogenesis·2024
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Certain human viruses, like Hepatitis B Virus (HBV) and Human Papillomavirus (HPV), are oncogenic and act as cofactors in cancer development. Understanding these viruses aids in cancer diagnosis, prognosis, and developing future therapies like vaccines.

Area of Science:

  • Virology
  • Oncology
  • Molecular Biology

Context:

  • A limited number of human viruses possess oncogenic properties.
  • These viruses are implicated as cofactors in the complex process of carcinogenesis.
  • Epidemiologic and molecular studies support the viral role in cancer development.

Purpose:

  • To review the oncogenic potential of specific human viruses.
  • To highlight the role of viruses as cofactors in carcinogenesis.
  • To discuss the diagnostic, prognostic, and therapeutic implications of understanding these viral associations with cancer.

Summary:

  • Human viruses such as Human T-lymphotropic Virus (HTLV-1 and 2), Hepatitis B Virus (HBV), Epstein-Barr Virus (EBV), and Human Papillomavirus (HPV) are known to have oncogenic properties.

Related Experiment Videos

  • These viruses act as cofactors in the multistep process of carcinogenesis, as evidenced by epidemiologic and molecular studies.
  • Diagnostic tools like viral DNA probes and antibodies, and prognostic markers for HPV, are valuable in cancer management. Future therapeutic strategies, including vaccination against HBV to prevent hepatocellular carcinoma, are promising.

    • Impact:

    • Viral DNA probes and antibodies offer valuable diagnostic and prognostic tools for virus-associated cancers.
    • Enhanced knowledge of oncogenic viruses can lead to improved cancer prevention strategies, such as vaccination.
    • Further research into viral carcinogenesis may unlock novel therapeutic targets for cancer treatment.